<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ocrelizumab for multiple sclerosis - Lin, M - 2022 | Cochrane Library</title> <meta content="Ocrelizumab for multiple sclerosis - Lin, M - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013247.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ocrelizumab for multiple sclerosis - Lin, M - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013247.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013247.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Ocrelizumab for multiple sclerosis" name="citation_title"/> <meta content="Mengbing Lin" name="citation_author"/> <meta content="Second Affiliated Hospital of Guangxi Medical University" name="citation_author_institution"/> <meta content="Jian Zhang" name="citation_author"/> <meta content="Second Affiliated Hospital of Guangxi Medical University" name="citation_author_institution"/> <meta content="Yueling Zhang" name="citation_author"/> <meta content="Second Affiliated Hospital of Guangxi Medical University" name="citation_author_institution"/> <meta content="Jiefeng Luo" name="citation_author"/> <meta content="Second Affiliated Hospital of Guangxi Medical University" name="citation_author_institution"/> <meta content="Shengliang Shi" name="citation_author"/> <meta content="Second Affiliated Hospital of Guangxi Medical University" name="citation_author_institution"/> <meta content="ssl_1964@163.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD013247.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013247.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013247.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013247.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized; Gadolinium [therapeutic use]; Interferon beta-1a [adverse effects]; *Multiple Sclerosis [drug therapy]; *Multiple Sclerosis, Relapsing-Remitting [drug therapy]; Recurrence" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013247.pub2&amp;doi=10.1002/14651858.CD013247.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZCrlluee";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013247\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013247\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013247.pub2",title:"Ocrelizumab for multiple sclerosis",firstPublishedDate:"May 18, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013247.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013247.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013247.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013247.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013247.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013247.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013247.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013247.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013247.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013247.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4643 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013247.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-sec-0100"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-sec-0094"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/appendices#CD013247-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/supinfo/CD013247StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/supinfo/CD013247StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ocrelizumab for multiple sclerosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#CD013247-cr-0004">Mengbing Lin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#CD013247-cr-0005">Jian Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#CD013247-cr-0006">Yueling Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#CD013247-cr-0007">Jiefeng Luo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information#CD013247-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Shengliang Shi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information/en#CD013247-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013247.pub2">https://doi.org/10.1002/14651858.CD013247.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013247-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013247-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013247-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013247-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013247-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013247-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013247-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013247-abs-0001" lang="en"> <section id="CD013247-sec-0001"> <h3 class="title" id="CD013247-sec-0001">Background</h3> <p>Ocrelizumab is a humanised anti‐CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in adults with relapsing‐remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Ocrelizumab is the only disease‐modifying therapy (DMT) approved for PPMS. In November 2017, the European Medicines Agency (EMA) also approved ocrelizumab as the first drug for people with early PPMS. Therefore, it is important to evaluate the benefits, harms, and tolerability of ocrelizumab in people with MS. </p> </section> <section id="CD013247-sec-0002"> <h3 class="title" id="CD013247-sec-0002">Objectives</h3> <p>To assess the benefits, harms, and tolerability of ocrelizumab in people with RRMS and PPMS. </p> </section> <section id="CD013247-sec-0003"> <h3 class="title" id="CD013247-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, CENTRAL, and two trials registers on 8 October 2021. We screened reference lists, contacted experts, and contacted the main authors of studies. </p> </section> <section id="CD013247-sec-0004"> <h3 class="title" id="CD013247-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) involving adults diagnosed with RRMS or PPMS according to the McDonald criteria, comparing ocrelizumab alone or associated with other medications, at the approved dose of 600 mg every 24 weeks for any duration, versus placebo or any other active drug therapy. </p> </section> <section id="CD013247-sec-0005"> <h3 class="title" id="CD013247-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD013247-sec-0006"> <h3 class="title" id="CD013247-sec-0006">Main results</h3> <p>Four RCTs met our selection criteria. The overall population included 2551 participants; 1370 treated with ocrelizumab 600 mg and 1181 controls. Among the controls, 298 participants received placebo and 883 received interferon beta‐1a. The treatment duration was 24 weeks in one study, 96 weeks in two studies, and at least 120 weeks in one study. One study was at high risk of allocation concealment and blinding of participants and personnel; all four studies were at high risk of bias for incomplete outcome data. </p> <p>For RRMS, compared with interferon beta‐1a, ocrelizumab was associated with: 1. lower relapse rate (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.52 to 0.73; 2 studies, 1656 participants; moderate‐certainty evidence); 2. a lower number of participants with disability progression (hazard ratio (HR) 0.60, 95% CI 0.43 to 0.84; 2 studies, 1656 participants; low‐certainty evidence); 3. little to no difference in the number of participants with any adverse event (RR 1.00, 95% CI 0.96 to 1.04; 2 studies, 1651 participants; moderate‐certainty evidence); 4. little to no difference in the number of participants with any serious adverse event (RR 0.79, 95% CI 0.57 to 1.11; 2 studies, 1651 participants; low‐certainty evidence); 5. a lower number of participants experiencing treatment discontinuation caused by adverse events (RR 0.58, 95% CI 0.37 to 0.91; 2 studies, 1651 participants; low‐certainty evidence); 6. a lower number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging (MRI) (RR 0.27, 95% CI 0.22 to 0.35; 2 studies, 1656 participants; low‐certainty evidence); 7. a lower number of participants with new or enlarging T2‐hyperintense lesions on MRI (RR 0.63, 95% CI 0.57 to 0.69; 2 studies, 1656 participants; low‐certainty evidence) at 96 weeks. </p> <p>For PPMS, compared with placebo, ocrelizumab was associated with: 1. a lower number of participants with disability progression (HR 0.75, 95% CI 0.58 to 0.98; 1 study, 731 participants; low‐certainty evidence); 2. a higher number of participants with any adverse events (RR 1.06, 95% CI 1.01 to 1.11; 1 study, 725 participants; moderate‐certainty evidence); 3. little to no difference in the number of participants with any serious adverse event (RR 0.92, 95% CI 0.68 to 1.23; 1 study, 725 participants; low‐certainty evidence); 4. little to no difference in the number of participants experiencing treatment discontinuation caused by adverse events (RR 1.23, 95% CI 0.55 to 2.75; 1 study, 725 participants; low‐certainty evidence) for at least 120 weeks. There were no data for number of participants with gadolinium‐enhancing T1 lesions on MRI and number of participants with new or enlarging T2‐hyperintense lesions on MRI. </p> </section> <section id="CD013247-sec-0007"> <h3 class="title" id="CD013247-sec-0007">Authors' conclusions</h3> <p>For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta‐1a at 96 weeks (moderate‐certainty evidence). Ocrelizumab may result in a large reduction in disability progression, treatment discontinuation caused by adverse events, number of participants with gadolinium‐enhancing T1 lesions on MRI, and number of participants with new or enlarging T2‐hyperintense lesions on MRI, and may result in little to no difference in serious adverse events (low‐certainty evidence). </p> <p>For people with PPMS, ocrelizumab probably results in a higher rate of adverse events when compared with placebo for at least 120 weeks (moderate‐certainty evidence). Ocrelizumab may result in a reduction in disability progression and little to no difference in serious adverse events and treatment discontinuation caused by adverse events (low‐certainty evidence). </p> <p>Ocrelizumab was well tolerated clinically; the most common adverse events were infusion‐related reactions and nasopharyngitis, and urinary tract and upper respiratory tract infections. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013247-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013247-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013247-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013247-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013247-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013247-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013247-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013247-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013247-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013247-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013247-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013247-abs-0002" lang="en"> <h3>What are the benefits and risks of ocrelizumab for multiple sclerosis?</h3> <p><b>Key messages</b> </p> <p>– Ocrelizumab is a recently approved medicine to treat people with multiple sclerosis (MS). In relapsing‐remitting MS (where people experience flare‐ups of symptoms), ocrelizumab probably substantially reduces flare‐ups, may substantially reduce worsening of symptoms, and probably makes little or no difference to unwanted effects compared with interferon beta‐1a (a standard treatment for MS), 96 weeks after treatment starts. </p> <p>– Compared to placebo (a dummy medicine) after 120 weeks of treatment for primary progressive MS (where people's symptoms worsen gradually), ocrelizumab may reduce worsening of symptoms. Ocrelizumab probably increases unwanted effects but makes little or no difference to the number of serious unwanted effects. </p> <p>– We need more, better‐designed studies to test the effectiveness of ocrelizumab and measure unwanted effects.  </p> <p><b>What is multiple sclerosis?</b> </p> <p>MS is a condition where the body's immune system mistakenly attacks the nerves in the brain and spinal cord (the central nervous system). This damage prevents messages travelling from the central nervous system to other parts of the body. It causes a range of potential symptoms from pins and needles to difficulties with balance and walking.  </p> <p>There are several types of MS. In relapsing‐remitting MS, people have 'flare‐ups' of disease followed by periods of recovery. In primary progressive MS, people's symptoms gradually worsen over time.  </p> <p><b>What is ocrelizumab?</b> </p> <p>Ocrelizumab is a medicine that has been recently approved to treat relapsing‐remitting MS and primary progressive MS. It is a disease‐modifying therapy, which is a type of medicine that treats the underlying symptoms of MS. Ocrelizumab targets white blood cells in the body's immune system. It sticks to a type of these cells called B cells, and stops them attacking the central nervous system. This prevents inflammation and nerve damage, reducing the number and severity of relapses and slowing the worsening of symptoms. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if ocrelizumab is more effective than any other medicine or placebo in people with relapsing‐remitting MS and primary progressive MS. </p> <p>We were interested in how many people:</p> <p>– had symptom flare‐ups;</p> <p>– had worsening symptoms;</p> <p>– experienced unwanted effects; and</p> <p>– stopped treatment due to unwanted effects.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared ocrelizumab against any other medicine or placebo for people with a confirmed diagnosis of relapsing‐remitting MS or primary progressive MS. People in the studies could be any age or sex, could have mild or severe symptoms, and could have had MS for any length of time. </p> <p>We compared and summarised their results, and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found four studies with 2551 people with MS. The largest study included 732 people and the smallest included 163 people. The studies were in countries around the world, but mostly in the USA. One study lasted for 24 weeks; two studies for 96 weeks; and one study for at least 120 weeks. Pharmaceutical companies funded the four studies. </p> <p>Three studies compared ocrelizumab with interferon beta‐1a in people with relapsing‐remitting MS. Interferon beta‐1a is an older type of disease‐modifying therapy. One study compared ocrelizumab with placebo for people with primary progressive MS. </p> <p><b>Main results</b> </p> <p>Ocrelizumab compared with interferon beta‐1a for people with relapsing‐remitting MS, after 96 weeks of treatment: </p> <p>– probably substantially reduces the number of people who had flare‐ups;</p> <p>– may substantially reduce the number of people whose symptoms got worse;</p> <p>– probably makes little or no difference to unwanted effects; and </p> <p>– may substantially reduce the number of people who stopped having treatment due to unwanted effects.  </p> <p>Ocrelizumab compared with placebo for people with primary progressive MS, after 120 weeks of treatment: </p> <p>– may reduce the number of people whose symptoms got worse; </p> <p>– probably increases unwanted effects;  and</p> <p>– may make little or no difference to the number of serious unwanted effects and the number of people who stopped having treatment due to unwanted effects. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the results is moderate to low for several reasons. First, people dropped out of the studies unevenly, which meant more people had one treatment than the other. Second, there was not enough information about some of our points of interest to allow us to draw conclusions for outcomes, there was not enough information available for us to be confident in the results. Finally, changes in symptoms shown by scans could have been due to causes other than disease progression. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is up‐to‐date to 8 October 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013247-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013247-sec-0100"></div> <h3 class="title" id="CD013247-sec-0101">Implications for practice</h3> <section id="CD013247-sec-0101"> <p>For people with relapsing‐remitting multiple sclerosis (RRMS), ocrelizumab probably results in a large reduction in relapse rate and probably results in little to no difference in adverse events when compared with interferon beta‐1a at 96 weeks (moderate‐certainty evidence). Ocrelizumab may result in a large reduction in disability progression, treatment discontinuation caused by adverse events, number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging (MRI), and number of participants with new or enlarging T2‐hyperintense lesions on MRI; and may result in little to no difference in serious adverse events (low‐certainty evidence). </p> <p>For people with PPMS, ocrelizumab probably results in a higher rate of adverse events when compared with placebo for at least 120 weeks (moderate‐certainty evidence). Ocrelizumab may result in a reduction in disability progression and may result in little to no difference in serious adverse events and treatment discontinuation caused by adverse events (low‐certainty evidence). </p> <p>Ocrelizumab was well tolerated clinically, with infusion‐related reactions and nasopharyngitis, and urinary tract and upper respiratory tract infections being the most common adverse events. </p> <p>Based on these results, clinicians may consider ocrelizumab as an effective and safe treatment to be offered to people with RRMS and PPMS. </p> </section> <h3 class="title" id="CD013247-sec-0102">Implications for research</h3> <section id="CD013247-sec-0102"> <p>The included trials did not report all the critical and important outcomes which should be addressed in the planning of future research. The feasibility of using ocrelizumab in combination with modified therapies for other diseases remains to be further tested. More randomised, double‐blind, large‐sample controlled trials are required in the future to evaluate the benefits, harms, and tolerability of ocrelizumab for RRMS and PPMS. In particular, treatment duration and follow‐up needs to be longer. Further studies could result in increased certainty in the evidence, as the current evidence offers only low to moderate certainty in the outcomes of interest. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013247-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013247-sec-0008"></div> <div class="table" id="CD013247-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ocrelizumab compared to interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ocrelizumab compared to interferon beta‐1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with relapsing‐remitting multiple sclerosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ocrelizumab<br/><b>Comparison:</b> interferon beta‐1a </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with interferon beta‐1a</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with ocrelizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing ≥ 1 relapse</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.61</b><br/>(0.52 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1000<br/>(201 to 274) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing disability progression</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.60</b><br/>(0.43 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000<br/>(50 to 94) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any adverse events</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b><br/>(0.96 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1000<br/>(800 to 866) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any serious adverse events</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.79</b><br/>(0.57 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000<br/>(50 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse events</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.58</b><br/>(0.37 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/>(22 to 55) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with gadolinium‐enhancing T1 lesions on MRI</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.27</b><br/>(0.22 to 0.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>331 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/>(73 to 116) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with new or enlarging T2‐hyperintense lesions on MRI</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.63</b><br/>(0.57 to 0.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>616 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>388 per 1000<br/>(351 to 425) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MRI:</b> magnetic resonance imaging; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to study limitation (a high rate of dropouts existed and reasons of dropouts were unbalanced between arms).<br/><sup>b</sup>Downgraded one level due to imprecision (total number of events (i.e. the number of participants experiencing disability progression, the number of participants with any serious adverse events and the number of participants experiencing treatment discontinuation caused by adverse events) was fewer than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size (OIS) criteria. Wide 95% confidence intervals).<br/><sup>c</sup>Downgraded one level due to indirectness (changes in MRI (gadolinium‐enhancing T1 lesions or new or newly enlarging T2‐hyperintense lesions) were not consistently proved closely related to changes in disability progression). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013247-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ocrelizumab compared to placebo for primary progressive multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ocrelizumab compared to placebo for primary progressive multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with primary progressive multiple sclerosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ocrelizumab<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with ocrelizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing disability progression</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.75</b><br/>(0.58 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>731<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(239 to 367) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any adverse events</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b><br/>(1.01 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>725<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>954 per 1000<br/>(909 to 999) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any serious adverse events</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.92</b><br/>(0.68 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>725<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000<br/>(151 to 273) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse event</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.23</b><br/>(0.55 to 2.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>725<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/>(18 to 92) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with gadolinium‐enhancing T1 lesions on MRI</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with new or enlarging T2‐hyperintense lesions on MRI</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to study limitation (a high rate of dropouts existed and reasons of dropouts were unbalanced between arms).<br/><sup>b</sup>Downgraded one level due to imprecision (total number of events (i.e. the number of participants experiencing disability progression, the number of participants with any serious adverse events, and the number of participants experiencing treatment discontinuation caused by adverse events) was fewer than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size (OIS) criteria. Wide 95% confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013247-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013247-sec-0009"></div> <section id="CD013247-sec-0010"> <h3 class="title" id="CD013247-sec-0010">Description of the condition</h3> <p>Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that can cause neurological relapses that may partially or fully resolve, as well as disability accumulation. Neurodegeneration is a fundamental aspect of MS pathogenesis as loss of axons, dendrites, and neurons is a major cause of permanent neurological disability in people with MS (<a href="./references#CD013247-bbs2-0010" title="DuttaR , TrappBD .Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Progress in Neurobiology2011;93(1):1-12.">Dutta 2011</a>). Current studies support inflammatory cascade as the underlying cause of oligodendrocytes and myelin sheath loss during earlier stages in MS (<a href="./references#CD013247-bbs2-0008" title="Dhib-JalbutS .Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology2007;68(22 Suppl 3):13-21.">Dhib‐Jalbut 2007</a>). Epidemiological studies have shown that the distribution of MS can be attributed to differences in genetic, particularly the HLA‐DR15 haplotype, and environmental factors and their interactions. The prevalence of MS is lowest at the equator and increases with north and south latitude (<a href="./references#CD013247-bbs2-0018" title="Koch-HenriksenN , SørensenPS .The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology2010;9(5):520-32.">Koch‐Henriksen 2010</a>). With an incidence of 2 per 100,000 in Asia and more than 100 per 100,000 in Northern Europe and North America, the burden of MS is similarly affected by unevenness in longevity and comorbidity (<a href="./references#CD013247-bbs2-0016" title="HowardJ , TrevickS , YoungerDS .Epidemiology of multiple sclerosis. Neurologic Clinics2016;34(4):919-39.">Howard 2016</a>). </p> <p>The most common clinical manifestations of MS are optic neuritis, brainstem and spinal cord syndromes, and other less common symptoms, including cortical presentations such as dominant parietal lobe syndromes (<a href="./references#CD013247-bbs2-0009" title="DobsonR , GiovannoniG .Multiple sclerosis – a review. European Journal of Neurology2019;26(1):27-40.">Dobson 2019</a>). Clinical manifestations are often varied because of the site of neurological involvement. The International Advisory Committee on Clinical Trials of Multiple Sclerosis has reviewed the disease phenotypes, including consideration of disease activity based on clinical relapses, disease progression, and imaging findings. About 85% of people have a relapsing‐remitting (RRMS) course, characterised by a course of deteriorations and remissions. The course of secondary progressive MS (SPMS) is characterised by gradual deterioration after an initial relapsing disease course with or without acute deteriorations during the progressive course (<a href="./references#CD013247-bbs2-0020" title="LublinFD , ReingoldSC , CohenJA , CutterGR , SørensenPS , ThompsonAJ , et al.Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2015;83(3):278-86.">Lublin 2014</a>). Primary progressive MS (PPMS) is a part of progressive MS phenotypes; it enters a progressive course from onset without a relapsing course (<a href="./references#CD013247-bbs2-0020" title="LublinFD , ReingoldSC , CohenJA , CutterGR , SørensenPS , ThompsonAJ , et al.Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2015;83(3):278-86.">Lublin 2014</a>). </p> <p>Current immunomodulatory drugs for the treatment of RRMS include interferon beta‐1a, interferon beta‐1b, peginterferon beta‐1a, glatiramer acetate, alemtuzumab, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, ocrelizumab, daclizumab (withdrawn in 2018), cladribine, siponimod, ozanimod, and ponesimod (<a href="./references#CD013247-bbs2-0024" title="National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).LiverTox: Clinical and Research Information on Drug-Induced Liver Injury – Multiple Sclerosis Agents. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2021.">NIDDK 2021</a>; <a href="./references#CD013247-bbs2-0030" title="RotsteinD , MontalbanX .Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nature Reviews Neurology2019;15(5):287-300.">Rotstein 2019</a>). Ocrelizumab is the only immunomodulatory agent approved for PPMS (<a href="./references#CD013247-bbs2-0030" title="RotsteinD , MontalbanX .Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nature Reviews Neurology2019;15(5):287-300.">Rotstein 2019</a>). The reduction in relapse and disability progression risk varies between disease‐modifying therapies (DMT) (<a href="./references#CD013247-bbs2-0013" title="FogartyE , SchmitzS , TubridyN , WalshC , BarryM .Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Multiple Sclerosis and Related Disorders2017;9(001):23-30.">Fogarty 2017</a>). At present, MS is incurable. DMTs are targeted to reduce the risk of relapses and disability progression. </p> </section> <section id="CD013247-sec-0011"> <h3 class="title" id="CD013247-sec-0011">Description of the intervention</h3> <p>Ocrelizumab is a humanised anti‐CD20 monoclonal antibody which was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of RRMS or PPMS (<a href="./references#CD013247-bbs2-0011" title="US Food and Drug Administration.FDA approves new drug to treat multiple sclerosis. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm (accessed 28 April 2022).">FDA 2017</a>). While a series of DMTs have been approved for RRMS, ocrelizumab is the only DMT approved for PPMS (<a href="./references#CD013247-bbs2-0032" title="SyedYY .Ocrelizumab: a review in multiple sclerosis. CNS Drugs2018;32(9):883-90.">Syed 2018</a>). This capability has attracted the attention of researchers interested in studying the benefits, harms, and tolerability of ocrelizumab. Treatment with ocrelizumab is associated with adverse events, such as infusion‐related reactions, upper respiratory tract infection, nasopharyngitis, urinary tract infection, and headache. </p> </section> <section id="CD013247-sec-0012"> <h3 class="title" id="CD013247-sec-0012">How the intervention might work</h3> <p>CD20, an activated‐glycosylated phosphoprotein, is a cell surface antigen found on pre‐B cells and mature and memory B‐cells (<a href="./references#CD013247-bbs2-0031" title="SorensenPS , BlinkenbergM .The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders2016;9(1):44-52.">Sorensen 2016</a>). Bubien and colleagues have suggested that B‐cells play a central role in the pathogenesis of MS. During antigen recognition by immature and mature B‐cells, CD20 is transduced through the B‐cell antigen receptor (<a href="./references#CD013247-bbs2-0005" title="BubienJK , ZhouLJ , BellPD , FrizzellRA , TedderTF .Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. Journal of Cell Biology1993;121(5):1121-32.">Bubien 1993</a>). The following mechanisms of B‐cell depletion have been suggested: </p> <p> <ol id="CD013247-list-0001"> <li> <p>"complement‐dependent cytotoxicity characterised by the formation of pores in the cell membrane, causing breakdown of the cell membrane leading to cell lysis" (<a href="./references#CD013247-bbs2-0031" title="SorensenPS , BlinkenbergM .The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders2016;9(1):44-52.">Sorensen 2016</a>); </p> </li> <li> <p>"antibody‐dependent cellular cytotoxicity involving macrophages, natural killer cells, and cytotoxic T cells that act together to cause cell destruction" (<a href="./references#CD013247-bbs2-0031" title="SorensenPS , BlinkenbergM .The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders2016;9(1):44-52.">Sorensen 2016</a>); </p> </li> <li> <p>"apoptosis, which occurs through cross‐linking membrane CD20 on the target cell surface" (<a href="./references#CD013247-bbs2-0007" title="ClynesRA , TowersTL , PrestaLG , RavetchJV .Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine2000;6(4):443-6.">Clynes 2000</a>; <a href="./references#CD013247-bbs2-0028" title="ReffME , CarnerK , ChambersKS , ChinnPC , LeonardJE , RaabR , et al.Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood1994;83(2):435-45.">Reff 1994</a>; <a href="./references#CD013247-bbs2-0031" title="SorensenPS , BlinkenbergM .The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders2016;9(1):44-52.">Sorensen 2016</a>). </p> </li> </ol> </p> <p>Animal experiments suggest that the depletion of B‐cell may cause changes in the cytokine network, reducing pathogenic T‐cell responses and contributing to the favourable effect of anti‐CD20 treatment in MS (<a href="./references#CD013247-bbs2-0019" title="LiR , RezkA , MiyazakiY , HilgenbergE , TouilH , ShenP , et al.Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Science Translational Medicine2015;7(310):310ra166.">Li 2015</a>). Ocrelizumab, as a humanised anti‐CD20 monoclonal antibody, depletes B‐cells ranging from pro‐B‐cells to short‐lived plasmablasts. <a href="./references#CD013247-bbs2-0025" title="PalanichamyA , JahnS , NicklesD , DerstineM , AbounasrA , HauserSL , et al.Rituximab efficiently depletes increased CD20-expressing TcCells in multiple sclerosis patients. Journal of Immunology2014;193(2):580-6.">Palanichamy 2014</a> proposes that anti‐CD20 treatment not only depletes B‐cells, it also depletes CD20+ T cells. Memory B‐cells mediate autoproliferation of peripheral Th1 cells in an HLA‐DR‐dependent manner in people carrying the HLA‐DR15 haplotype. Depletion of B cells in vitro and therapeutically in vivo by anti‐CD20 effectively reduces autoproliferation of T‐cells (<a href="./references#CD013247-bbs2-0017" title="JelcicI , Al NimerF , WangJ , LentschV , PlanasR , JelcicI , et al.Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell2018;175(1):85-100.">Jelcic 2018</a>). </p> <p>For MS, B‐cell‐depleting treatment‐related monoclonal anti‐CD20 antibodies includes rituximab, ocrelizumab, and ofatumumab. Compared with rituximab, ocrelizumab more effectively causes a pathogenic response in vivo; it also increases the antibody‐dependent cell‐mediated cytotoxicity and reduces the complement‐dependent cytotoxicity (<a href="./references#CD013247-bbs2-0031" title="SorensenPS , BlinkenbergM .The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders2016;9(1):44-52.">Sorensen 2016</a>). Compared with rituximab, ocrelizumab has lower immunogenicity and is less likely to induce human anti‐human antibodies in repeated injections (<a href="./references#CD013247-bbs2-0031" title="SorensenPS , BlinkenbergM .The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders2016;9(1):44-52.">Sorensen 2016</a>). </p> </section> <section id="CD013247-sec-0013"> <h3 class="title" id="CD013247-sec-0013">Why it is important to do this review</h3> <p>Ocrelizumab was approved by the US FDA to treat adults with RRMS and PPMS in March 2017. This was the first drug approved by the FDA for PPMS. In November 2017, the European Medicines Agency (EMA) approved ocrelizumab as the first medicine to receive a positive endorsement for treatment of people with early‐stage PPMS. Therefore, it is important to assess the benefit–risk ratio of ocrelizumab for people with MS. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013247-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013247-sec-0014"></div> <p>To assess the benefits, harms, and tolerability of ocrelizumab in people with RRMS and PPMS. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013247-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013247-sec-0015"></div> <section id="CD013247-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013247-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with blinded assessment of participants, personnel, and outcomes. </p> </section> <section id="CD013247-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants with a confirmed diagnosis of RRMS or PPMS, according to published criteria (<a href="./references#CD013247-bbs2-0022" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121-7.">McDonald 2001</a>; <a href="./references#CD013247-bbs2-0026" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al.Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840-6.'>Polman 2005</a>; <a href="./references#CD013247-bbs2-0027" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292-302.">Polman 2011</a>; <a href="./references#CD013247-bbs2-0033" title="ThompsonAJ , BanwellBL , BarkhofF , CarrollWM , CoetzeeT , ComiG , et al.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology2018;17(2):162-73.">Thompson 2018</a>), regardless of age, sex, degree of disability, or duration of the disease. And we excluded participants with other clinically significant autoimmune disorder or previous immunosuppressive before. </p> </section> <section id="CD013247-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Experimental intervention: ocrelizumab alone or associated with other medications at the approved dose of 600 mg every 24 weeks for any course duration. </p> <p>Comparator: placebo, any other active drug therapy (i.e. corticosteroids, plasmapheresis, beta interferons, glatiramer acetate, natalizumab, alemtuzumab, daclizumab, mitoxantrone, fingolimod, dimethyl fumarate, or teriflunomide). </p> <p>Concomitant interventions were allowed only if used equally in all arms of the trial.</p> </section> <section id="CD013247-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We assessed the following outcomes at the end of the treatment period.</p> <section id="CD013247-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD013247-sec-0022"> <h6 class="title">Benefits</h6> <p> <ol id="CD013247-list-0002"> <li> <p>Number of participants experiencing at least one relapse at one year and after, or at the end of the study. Relapse was defined as the appearance of one or more new symptoms due to MS or the deterioration of pre‐existing symptoms, persisting more than 24 hours in the absence of fever and preceded by a period of stability of at least one month (<a href="./references#CD013247-bbs2-0022" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121-7.">McDonald 2001</a>). </p> </li> <li> <p>Number of participants experiencing disability progression at 24 weeks to week 96. Disability progression is defined as an increase from the baseline Expanded Disability Status Scale (EDSS) score of at least 1.0 point (or 0.5 points if the baseline EDSS score was greater than 5.5) that was sustained for at least 24 weeks. </p> </li> </ol> </p> </section> <section id="CD013247-sec-0023"> <h6 class="title">Harms</h6> <p> <ol id="CD013247-list-0003"> <li> <p>Number of participants experiencing any adverse event.</p> </li> <li> <p>Number of participants experiencing any serious adverse event. A serious adverse event was defined as any adverse event that, at any dose, fulfilled at least one of the following criteria: was fatal; was life‐threatening; required hospitalisation or prolongation of existing hospitalisation; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above. </p> </li> <li> <p>Number of participants experiencing treatment discontinuation caused by adverse events.</p> </li> </ol> </p> </section> </section> <section id="CD013247-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013247-list-0004"> <li> <p>Change in quality of life at one year and after, or at the end of the study. The following scales were accepted: 36‐item Short‐Form Health Survey (SF‐36) scores (<a href="./references#CD013247-bbs2-0036" title="Ware JE Jr, SherbourneCD .The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):473-83.">Ware 1992</a>), Multiple Sclerosis Quality of Life (MSQoL‐54) questionnaire scores (<a href="./references#CD013247-bbs2-0035" title="VickreyBG , HaysRD , HarooniR , MyersLW , EllisonGW .A health-related quality of life measure for multiple sclerosis. Quality of Life Research1995;4(3):187-206.">Vickrey 1995</a>), Multiple Sclerosis Quality of Life Inventory (MSQLI) (<a href="./references#CD013247-bbs2-0012" title="FischerJS , LaRoccaNG , MillerDM , RitvoPG , AndrewsH , PatyD .Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis1999;5(4):251-9.">Fischer 1999</a>), or Functional Assessment of Multiple Sclerosis (FAMS) (<a href="./references#CD013247-bbs2-0006" title="CellaDF , DineenK , ArnasonB , RederA , WebsterKA , KarabatsosG , et al.Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument. Neurology1996;47(1):129-39.">Cella 1996</a>). </p> </li> <li> <p>Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging (MRI) at one year and after, or at the end of the study. </p> </li> <li> <p>Number of participants with new or enlarging T2‐hyperintense lesions on MRI at one year and after, or at the end of the study. </p> </li> <li> <p>Brain volume changed at one year and after, or at the end of the study.</p> </li> </ol> </p> </section> </section> </section> <section id="CD013247-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013247-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the following on 8 October 2021:</p> <p> <ol id="CD013247-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library) (2021 Issue 9); </p> </li> <li> <p>MEDLINE (PubMed) (from 1966);</p> </li> <li> <p>Embase (<a href="http://Embase.com" target="_blank">Embase.com</a>) (from 1974); </p> </li> <li> <p>ClinicalTrials.gov (www.clinicaltrials.gov) for all prospectively registered trials (from 2000); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>) (from 2005). </p> </li> </ol> </p> <p>The full search strategies are listed in <a href="./appendices#CD013247-sec-0106">Appendix 1</a>, <a href="./appendices#CD013247-sec-0107">Appendix 2</a>, <a href="./appendices#CD013247-sec-0108">Appendix 3</a>, <a href="./appendices#CD013247-sec-0109">Appendix 4</a>, and <a href="./appendices#CD013247-sec-0110">Appendix 5</a>. </p> </section> <section id="CD013247-sec-0027"> <h4 class="title">Searching other resources</h4> <p>In addition, we used the following methods.</p> <p> <ol id="CD013247-list-0006"> <li> <p>We screened reference lists of relevant review articles and primary studies found.</p> </li> <li> <p>We contacted experts in the field to identify further published or unpublished trials.</p> </li> <li> <p>We contacted the main authors of studies if data reported in the original articles were incomplete. </p> </li> </ol> </p> </section> </section> <section id="CD013247-sec-0028"> <h3 class="title" id="CD013247-sec-0028">Data collection and analysis</h3> <section id="CD013247-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Three review authors (ML, JZ, and JL) independently screened titles and abstracts of the citations retrieved by the literature search to obtain titles and abstracts of studies possibly relevant to the review. We obtained full copies of potentially relevant studies for further assessment. We also independently evaluated the eligibility of these studies on the basis of information available in the published data. We excluded irrelevant studies. We resolved disagreements through discussion. </p> </section> <section id="CD013247-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (ML, JZ and JL) independently extracted data from selected trials using standardised forms, and entered the data into Review Manager 5 (<a href="./references#CD013247-bbs2-0029" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>).<br/>We extracted the following information from individual studies. </p> <p> <ol id="CD013247-list-0007"> <li> <p>Publication details (i.e. year, data, country, journal, authors).</p> </li> <li> <p>Study design and setting: inclusion criteria, exclusion criteria, number of randomised participants and characteristics of participants. </p> </li> <li> <p>Details of intervention (i.e. doses, frequency, scheme, length).</p> </li> <li> <p>Description of outcomes.</p> </li> <li> <p>Risk of bias: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other bias. </p> </li> <li> <p>Data analyses.</p> </li> <li> <p>Declarations of interest and funding source.</p> </li> </ol> </p> <p>We resolved disagreements by discussion among the review authors.</p> </section> <section id="CD013247-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (ML, JZ, and YZ) independently assessed the risks of bias in included studies, using the Cochrane risk of bias criteria (<a href="./references#CD013247-bbs2-0015" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). We assessed the following domains. </p> <p> <ol id="CD013247-list-0008"> <li> <p>Sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other potential sources of bias.</p> </li> </ol> </p> <p>We judged each domain as being at low, high, or unclear risk of bias. And we resolved any disagreements by discussion among all review authors. We judged the overall risk of bias of each included study according to the following criteria. </p> <p> <ol id="CD013247-list-0009"> <li> <p>Low risk of bias (plausible bias unlikely to seriously alter the results) if all the above items were met. </p> </li> <li> <p>Unclear risk of bias (plausible bias that raises some doubt about the results) if one or more items were assessed as unclear. </p> </li> <li> <p>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more items were not met. </p> </li> </ol> </p> </section> <section id="CD013247-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed data using Review Manager 5 (<a href="./references#CD013247-bbs2-0029" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We expressed results for dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs). We calculated mean differences (MD) with 95% CIs for continuous data. We used hazard ratio (HR) with 95% CIs if calculating time‐to‐event data. </p> </section> <section id="CD013247-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We included studies with parallel‐group design: participants randomly assigned to intervention or control were analysed at the individual allocation level. We planned to include cross‐over studies by considering only data from the first half of the cross‐over trial, but the search found no cross‐over studies. We performed each separate analysis based on the preset outcomes and different periods of follow‐up (24 and 96 weeks). </p> </section> <section id="CD013247-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of identified studies to obtain additional information. If additional information was not obtained, we analysed the available data. </p> </section> <section id="CD013247-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated clinical and methodological heterogeneity across included studies by comparing characteristics of participants, interventions, and study designs. </p> <p>We evaluated statistical heterogeneity among included studies using a Chi² test with an alpha of 0.1, and with the I² test. A P value of less than 0.1 and an I² statistic more than 50% was an indication of substantial statistical heterogeneity (<a href="./references#CD013247-bbs2-0015" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>); we examined potential sources of clinical and methodological heterogeneity. </p> </section> <section id="CD013247-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not use funnel plots to explore possible publication bias due to an insufficient number of included studies. </p> </section> <section id="CD013247-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 to conduct formal meta‐analysis (<a href="./references#CD013247-bbs2-0029" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). The selection of a fixed‐effect or random‐effects model was mainly based on the results of the Chi² test and I² statistic for heterogeneity (<a href="./references#CD013247-bbs2-0015" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). If the I² statistic indicated substantial statistical heterogeneity, we explored potential causes of heterogeneity first, to determine whether a subgroup analyses was needed. If the substantial heterogeneity still could not be explained, we adopted a random‐effects model. If the I² statistic indicated no significant statistical heterogeneity, we used a fixed‐effect model. </p> </section> <section id="CD013247-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroups analyses.</p> <p> <ol id="CD013247-list-0010"> <li> <p>Different dosages of ocrelizumab.</p> </li> <li> <p>Different duration of treatment.</p> </li> <li> <p>Different degrees of disability.</p> </li> <li> <p>Different co‐interventions.</p> </li> <li> <p>Different types of interferon beta‐1a.</p> </li> </ol> </p> <p>However, we did not carry out subgroup analyses to consider dosages of ocrelizumab, baseline degree of disability, cointerventions, and types of interferon beta‐1a due to lack of available data. </p> </section> <section id="CD013247-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis by excluding trials at high risk of bias (i.e. non‐random sequence generation and inadequate allocation concealment, lack of blinded outcome assessor, lack of blinded participants/personnel, or a combination of these). However, because of the limited number of studies, we deemed this analysis inappropriate. </p> </section> <section id="CD013247-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>In the summary of findings tables, we included trials with a follow‐up period longer than 12 months. We created two summary of findings tables comparing intravenous ocrelizumab at the approved dose of 600 mg every 24 weeks; one versus subcutaneous interferon beta‐1a 44 μg three times weekly for RRMS at 96 weeks (<a href="./full#CD013247-tbl-0001">summary of findings Table 1</a>), and one versus placebo for PPMS at 120 weeks (<a href="./full#CD013247-tbl-0002">summary of findings Table 2</a>). </p> <p>In <a href="./full#CD013247-tbl-0001">summary of findings Table 1</a>, we included seven outcomes. </p> <p> <ol id="CD013247-list-0011"> <li> <p>Number of participants experiencing at least one relapse.</p> </li> <li> <p>Number of participants experiencing disability progression.</p> </li> <li> <p>Number of participants with any adverse event.</p> </li> <li> <p>Number of participants with any serious adverse events.</p> </li> <li> <p>Number of participants experiencing treatment discontinuation caused by adverse events.</p> </li> <li> <p>Number of participants with gadolinium‐enhancing T1 lesions on MRI.</p> </li> <li> <p>Number of participants with new or enlarging T2‐hyperintense lesions on MRI.</p> </li> </ol> </p> <p>In <a href="./full#CD013247-tbl-0002">summary of findings Table 2</a>, we included six outcomes. </p> <p> <ol id="CD013247-list-0012"> <li> <p>Number of participants experiencing disability progression.</p> </li> <li> <p>Number of participants with any adverse event.</p> </li> <li> <p>Number of participants with any serious adverse events.</p> </li> <li> <p>Number of participants experiencing treatment discontinuation caused by adverse events.</p> </li> <li> <p>Number of participants with gadolinium‐enhancing T1 lesions on MRI.</p> </li> <li> <p>Number of participants with new or enlarging T2‐hyperintense lesions on MRI.</p> </li> </ol> </p> <p>We used the five GRADE parameters (risk of bias, inconsistency, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it related to the studies that contributed data to the meta‐analyses for prespecified outcomes. We used the methods and recommendations described in Section 8 and Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013247-bbs2-0015" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>) using the GRADEpro GDT (<a href="./references#CD013247-bbs2-0014" title="GRADEpro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 14 March 2022. Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to downgrade or upgrade the certainty of studies in the footnotes and made comments to aid readers' understanding of the review when necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013247-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013247-sec-0041"></div> <section id="CD013247-sec-0042"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD013247-sec-0119" title="">Characteristics of included studies</a> table. </p> <section id="CD013247-sec-0043"> <h4 class="title">Results of the search</h4> <p>The search strategies retrieved 1227 references. A total of 177 references were potentially eligible. After reading the full texts, we included these 140 records. They referred to four RCTs and 136 ancillary reports about these four primary studies. The flow diagram of the process of study identification and selection is presented in <a href="#CD013247-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013247-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013247-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013247-sec-0044"> <h4 class="title">Included studies</h4> <p>The four RCTs included 2551 participants (<a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>; <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>; <a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a>). <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> was a multicentric RCT comparing ocrelizumab versus intramuscular interferon beta‐1a or placebo for people with RRMS according to the McDonald criteria (<a href="./references#CD013247-bbs2-0022" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121-7.">McDonald 2001</a>). <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> were multicentric RCTs comparing ocrelizumab versus subcutaneous interferon beta‐1a for people with RRMS according to the McDonald criteria (<a href="./references#CD013247-bbs2-0027" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292-302.">Polman 2011</a>). <a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> was a multicentric RCT comparing ocrelizumab versus placebo for people with PPMS according to the McDonald criteria (<a href="./references#CD013247-bbs2-0026" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al.Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840-6.'>Polman 2005</a>). </p> <p>For people with RRMS, we identified three RCTs including 1819 participants (<a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>; <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> was a multi‐arm trial. <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> were two identical double‐arm trials. We did not merge multi‐arm trials involving ocrelizumab at different doses compared to interferon beta treatment or placebo and presented separate data for each arm. <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> included two cycles, we included the first cycle, which was a randomised designed. The RCTs used the following regimens. </p> <p> <ol id="CD013247-list-0013"> <li> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> was a phase II trial. The ocrelizumab 600 mg group had a dual infusion of 300 mg for days 1 and 15. The placebo group received placebo on days 1 and 15. The interferon beta‐1a group received intramuscular interferon beta‐1a (Avonex, Biogen Idec Inc) once a week for 24 weeks. </p> </li> <li> <p><a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> (from 31 August 2011 to 14 February 2013) was a phase III trial. Participants received intravenous ocrelizumab 600 mg (two 300‐mg infusions on days 1 and 15 for the first dose and as a single 600‐mg infusion thereafter) every 24 weeks or subcutaneous interferon beta‐1a (Rebif, EMD Serono) 44 μg three times weekly for 96 weeks. </p> </li> <li> <p><a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> (from 20 September 2011 to 28 March 2013) was a phase III trial. Participants received intravenous ocrelizumab 600 mg (two 300‐mg infusions on days 1 and 15 for the first dose and as a single 600‐mg infusion thereafter) every 24 weeks or subcutaneous interferon beta‐1a (Rebif, EMD Serono) 44 μg three times weekly for 96 weeks. </p> </li> </ol> </p> <p>For people with PPMS, we included one RCT including 732 participants (<a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a>). </p> <p> <ol id="CD013247-list-0014"> <li> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> (from 3 March 2011 to 27 November 2012) was a phase III trial. Participants received intravenous ocrelizumab 600 mg (administered as two 300‐mg infusions 14 days apart) every 24 weeks or matching placebo every 24 weeks for at least 120 weeks. </p> </li> </ol> </p> <p>Details of these RCTs are available in the <a href="./references#CD013247-sec-0119" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD013247-sec-0045"> <h4 class="title">Excluded studies</h4> <p>We excluded none of the potentially eligible studies.</p> </section> <section id="CD013247-sec-0046"> <h4 class="title">Studies awaiting classification</h4> <p>There are no studies awaiting classification.</p> </section> <section id="CD013247-sec-0047"> <h4 class="title">Ongoing studies</h4> <p>We identified no ongoing studies.</p> </section> </section> <section id="CD013247-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of each study is detailed in the <a href="./references#CD013247-sec-0119" title="">Characteristics of included studies</a> table. <a href="#CD013247-fig-0002">Figure 2</a> and <a href="#CD013247-fig-0003">Figure 3</a> present the risk of bias summary along with review authors' judgements about each risk of bias item for each included study. </p> <div class="figure" id="CD013247-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013247-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013247-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013247-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013247-sec-0049"> <h4 class="title">Allocation</h4> <p>All four included trials were reported as randomised with the use of an independent interactive Web‐response system. Thus, the four studies were at low risk of bias for random sequence generation. </p> <p>For allocation concealment, we classified <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> at high risk of bias because the participants in the interferon beta‐1a group were not blinded to allocation. We classified two studies at low risk of bias because they provided an adequate method to ensure allocation concealment  (<a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). We classified <a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> at unclear risk of bias because it did not provide enough information to allow judgement. </p> </section> <section id="CD013247-sec-0050"> <h4 class="title">Blinding</h4> <p>We considered <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> at high risk of performance bias (participants and personnel) because the treating investigator had access to benefits and harms data and interferon beta‐1a group was open label. We considered the other three studies at low risk of performance bias (<a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>; <a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a>). </p> <p>We considered all studies at low risk of detection bias (outcome assessment) because blinded raters evaluated the benefits and harms outcomes. </p> </section> <section id="CD013247-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>All four trials provided sufficient details about the number of, and the reasons for, dropouts. In <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>, the dropout rate was unbalanced between the four groups (ocrelizumab 600 mg: 8.9%; ocrelizumab 2000 mg: 12.7%; interferon beta‐1a: 7.27%; placebo: 0%). In <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>, the dropout rate was unbalanced between the ocrelizumab group (10.7%) and the interferon beta‐1a group (17.3%). In <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>, the dropout rate was unbalanced between the ocrelizumab group (13.7%) and the interferon beta‐1a group (23.4%). In <a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a>, the dropout rate was unbalanced between the ocrelizumab group (18.0%) and the placebo group (29.0%). Due to these imbalances, we classified all four trials at high risk of attrition bias. </p> </section> <section id="CD013247-sec-0052"> <h4 class="title">Selective reporting</h4> <p>All four trials reported all specified primary and secondary outcomes. We classified them at low risk of reporting bias. </p> </section> <section id="CD013247-sec-0053"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias.</p> </section> </section> <section id="CD013247-sec-0054"> <h3 class="title" id="CD013247-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD013247-tbl-0001"><b>Summary of findings 1</b> Ocrelizumab compared to interferon beta‐1a for relapsing‐remitting multiple sclerosis</a>; <a href="./full#CD013247-tbl-0002"><b>Summary of findings 2</b> Ocrelizumab compared to placebo for primary progressive multiple sclerosis</a> </p> <p>We defined three main comparisons, ocrelizumab versus interferon beta‐1a for RRMS, ocrelizumab versus placebo for RRMS, and ocrelizumab versus placebo for PPMS. </p> <p>We reported the main results concerning benefit and withdrawals due to adverse events of ocrelizumab at the approved dose of 600 mg compared to interferon beta‐1a for RRMS at 96 weeks in <a href="./full#CD013247-tbl-0001">summary of findings Table 1</a> and compared to placebo for PPMS at 120 weeks in <a href="./full#CD013247-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013247-sec-0055"> <h4 class="title">Comparison 1: ocrelizumab 600 mg versus interferon beta‐1a for relapsing‐remitting multiple sclerosis </h4> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>, <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>, and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> compared ocrelizumab versus interferon beta‐1a for treating RRMS (see <a href="./full#CD013247-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD013247-sec-0056"> <h5 class="title">Primary outcomes: benefits</h5> <section id="CD013247-sec-0057"> <h6 class="title">Number of participants experiencing at least one relapse</h6> <p>Three trials reported the number of participants experiencing at least one relapse (<a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>; <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> assessed the number of participants experiencing at least one relapse at 24 weeks. There was little to no difference between groups (RR 0.33, 95% CI 0.09 to 1.14; P = 0.08; 109 participants). <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> assessed the number of participants experiencing at least one relapse at 96 weeks. The rate of participants experiencing at least one relapse was lower with ocrelizumab than with interferon beta‐1a (RR 0.61, 95% CI 0.52 to 0.73; P &lt; 0.00001; I² = 0%; 1656 participants; fixed‐effect model; moderate‐certainty evidence) (<a href="./references#CD013247-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD013247-sec-0058"> <h6 class="title">Number of participants experiencing disability progression</h6> <p>Two trials reported the number of participants experiencing 24‐week confirmed disability progression at 96 weeks (<a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). The rate was lower with ocrelizumab than with interferon beta‐1a (HR 0.60, 95% CI 0.43 to 0.84; P = 0.003; I² = 0%; 1656 participants; fixed‐effect model) (<a href="./references#CD013247-fig-0005" title="">Analysis 1.2</a>). (We used HR to calculate this outcome due to time‐to‐event data.) </p> </section> </section> <section id="CD013247-sec-0059"> <h5 class="title">Primary outcomes: harms</h5> <p>Three trials reported adverse events and serious adverse events (<a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>; <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). </p> <section id="CD013247-sec-0060"> <h6 class="title">Number of participants experiencing any adverse event</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> assessed the number of participants experiencing any adverse events at 24 weeks. There was little to no difference between groups (RR 1.11, 95% CI 0.81 to 1.53; P = 0.51; 109 participants). <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> assessed the number of participants experiencing any adverse events at 96 weeks. There was little to no difference between groups (RR 1.00, 95% CI 0.96 to 1.04; P = 0.99; I² = 0%; 1651 participants; fixed‐effect model) (<a href="./references#CD013247-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD013247-sec-0061"> <h6 class="title">Number of participants experiencing any serious adverse events</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> assessed the number of participants experiencing any serious adverse events at 24 weeks. There was little to no difference between groups (RR 0.49, 95% CI 0.05 to 5.26; P = 0.56; 109 participants). <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> assessed the number of participants experiencing any serious adverse events at 96 weeks. There was little to no difference between groups (RR 0.79, 95% CI 0.57 to 1.11; P = 0.17; I² = 0%; 1651 participants; fixed‐effect model) (<a href="./references#CD013247-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD013247-sec-0062"> <h6 class="title">Number of participants experiencing treatment discontinuation caused by adverse events</h6> <p>Three trials reported the number of participants experiencing treatment discontinuation caused by adverse events (<a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>; <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> assessed the number of participants experiencing treatment discontinuation caused by adverse events at 24 weeks. There was little to no difference between groups (RR 1.96, 95% CI 0.18 to 21.02; P = 0.58; 109 participants). <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> assessed the number of participants experiencing treatment discontinuation caused by adverse events at 96 weeks. There rate of participants experiencing treatment discontinuation caused by adverse events was lower with ocrelizumab than with interferon beta‐1a (RR 0.58, 95% CI 0.37 to 0.91; P = 0.02; I² = 0%; 1651 participants; fixed‐effect model) (<a href="./references#CD013247-fig-0008" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD013247-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD013247-sec-0064"> <h6 class="title">Change in quality of life</h6> <p>Two trials reported the change in SF‐36 Physical Component Summary score from baseline to week 96 (<a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). The change in score was better with ocrelizumab than with interferon beta‐1a (MD 0.93, 95% CI 0.02 to 1.83; P = 0.04; I² = 0%; 1656 participants; fixed‐effect model; <a href="./references#CD013247-fig-0009" title="">Analysis 1.6</a>) </p> </section> <section id="CD013247-sec-0065"> <h6 class="title">Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging </h6> <p>Three trials reported the number of participants with gadolinium‐enhancing T1 lesions on MRI (<a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a>; <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> assessed the number of participants with gadolinium‐enhancing T1 lesions on MRI at 24 weeks. The rate was lower with ocrelizumab than with interferon beta‐1a (RR 0.44, 95% CI 0.25 to 0.77; P = 0.004; 109 participants). <a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a> and <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a> assessed the number of participants with gadolinium‐enhancing T1 lesions on MRI at 96 weeks. The rate was lower with ocrelizumab than with interferon beta‐1a (RR 0.27, 95% CI 0.22 to 0.35; P &lt; 0.00001; I² = 0%; 1656 participants; fixed‐effect model) (<a href="./references#CD013247-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD013247-sec-0066"> <h6 class="title">Number of participants with new or enlarging T2‐hyperintense lesions on magnetic resonance imaging </h6> <p>Two trials reported the number of participants with new or enlarging T2‐hyperintense lesions on MRI at 96 weeks (<a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). The rate was lower with ocrelizumab than with interferon beta‐1a (RR 0.63, 95% CI 0.57 to 0.69; P &lt; 0.00001; I² = 0%; 1656 participants; fixed‐effect model; <a href="./references#CD013247-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD013247-sec-0067"> <h6 class="title">Mean percentage change in brain‐volume from week 24 to the end of the study</h6> <p>Two trials reported the mean percentage change in brain‐volume from week 24 to week 96 (<a href="./references#CD013247-bbs2-0002" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;22(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. von Buedingen H-C, Shon NguyenQ , HarpC , Toghi EshghiS , EggersE , HermanA .Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study. Multiple Sclerosis Journal2017;23(3 Suppl 1):312. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA I 2017</a>; <a href="./references#CD013247-bbs2-0003" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , KapposL , HauserS , MontalbanX , TraboulseeA , WolinskyJ , et al.Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. ArnoldD , SprengerT , Bar-OrA , WolinskyJ , KapposL , KolindS , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HauserSL , KapposL , et al.Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Multiple Sclerosis2016;22(Suppl 3):514-5. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265. ArnoldDL , KapposL , HauserSL , MontalbanX , TraboulseeA , WolinskyJS , et al.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):284-5. BalcerL , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):56-7. BalcerLJ , HauserSL , KapposL , LeocaniL , SaidhaS , JulianL , et al.Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(1 Suppl 1):16-7. BarkhofF , KapposL , WolinskyJS , LiDK , Bar-OrA , HartungHP , et al.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology2019;93(19):e1778-86. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. BrochetB , HauserSL , MontalbanX , NaismithR , WolinskyJS , ManfriniM , et al.Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials. European Journal of Neurology2018;25(Suppl 2):322. CohanS , BenedictR , De SèzeJ , HauserS , KapposL , WolinskyJ , et al.Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology2018;90(15 Suppl 1):Meeting abstract. CreeBA , HanJ , PradhanA , MastermanD , WilliamsMJ .Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon β-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):320-1. CreeBA , PradhanA , PeiJ , WilliamsMJ .Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis and Related Disorders2021;52:103010. DaiglM , JhutiGS , McDougallF , BennettI .EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS). Value in Health2016;19(7):A435. DerfussT , HauserSL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Medical Weekly2016;146(Suppl 219):735. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. GiovannoniG , ArnoldDL , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies. Multiple Sclerosis2016;23(Suppl 3):837-8. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. GiovannoniG , KapposL , De SèzeJ , HauserS , OverellJ , KoendgenH , et al.Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. Multiple Sclerosis Journal2020;26(3 Suppl):222-3. GiovannoniG , KapposL , deSèzeJ , HauserSL , OverellJ , KoendgenH , et al.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials. European Journal of Neurology2022;29(4):1238-42. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):308-9. GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , PrajapatiK , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):537-8. GobbiC , ArnoldDL , Bar-OrA , HartungHP , HauserSL , LublinF , et al.Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):72S. GouiderR , GiovannoniG , KapposL , HauserSL , MontalbanX , KoendgenH , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2020;37:101593. GreenAJ , Cruz-HerranzA , WangQ , ZiemssenT , WolfS , MehtaL .Effect of ocrelizumab versus interferon β-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):29-30. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserS , BrochetB , MontalbanX , NaismithR , WolinskyJ , ManfriniM , et al.Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. HauserS , ComiG , Hartung H-P, LublinF , SelmajK , TraboulseeA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. HauserS , ComiG , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):751. HauserS , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , StrauliN , RaievskaA , HarpC , KoendgenH , KletzlH , et al.B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2021;27(1 Suppl):44-5. HauserSL , Bar-OrA , ComiG , GiovannoniG , HartungHP , HemmerB , et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine2017;376(3):221-34. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2018;26:265-6. HauserSL , BrochetB , MontalbanX , NaismithRT , WolinskyJS , ManfriniM , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2 Suppl):285-6. HauserSL , ComiGC , Hartung H-P, SelmajK , TraboulseeA , Bar-OrA , et al.Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies. Multiple Sclerosis2015;23(11 Suppl 1):61-2. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , HartungHP , BrochetB , MontalbanX , NaismithRT , WolinskyJS , et al.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Clinical Neurophysiology2019;130(8):e170. HauserSL , KapposL , ArnoldDL , Bar-OrA , BrochetB , NaismithRT , et al.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology2020;95(13):e1854-67. HauserSL , KapposL , Bar-OrA , Hartung H-P, BelachewS , HanJ , et al.Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13-14. HauserSL , KapposL , GiovannoniG , MontalbanX , KoendgenH , WangQ , et al.Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS. Multiple Sclerosis Journal2020;26(1 Suppl):45-6. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):496. HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , ModelF , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HavrdovaE , ArnoldDL , BarorA , ComiG , GiovannoniG , Hartung H-P, et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials. European Journal of Neurology2017;24(Suppl 1):497. HavrdovaE , HauserS , HoneycuttW , KapposL , SelmajK , WolinskyJ , et al.No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , De SèzeJ , GiovannoniG , MontalbanX , WolinskyJ , BelachewS , et al.Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies. European Journal of Neurology2017;24(Suppl 1):572. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , TraboulseeAL , ArnoldDL , Bar-OrA , HartungHP , LublinF , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies. Swiss Medical Weekly2016;146(Suppl 219):46S. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , LublinF , WangQ , et al.Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):309-10. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurology2020;77(9):1132-40. KapposL , WolinskyJS , GiovannoniG , ArnoldDL , WangQ , BernasconiC , et al.Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2018;24(2 Suppl):256-7. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120. KrishnanA , SongZ , ClaytonD , GaetanoL , De CrespignyA , BengtssonT , et al.Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning. Multiple Sclerosis Journal2020;26(3 Suppl):120-1. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. LublinF , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a-controlled studies. European Journal of Neurology2016;23(Suppl 2):402. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. NaismithR , CascioneM , GrimaldiLM , HauserS , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open-label extension study. Neurology2017;88(16 Suppl 1):Meeting abstract. NaismithRT , CascioneM , GrimaldiLM , HauserSL , KapposL , MontalbanX , et al.Preliminary results of the OPERA I and OPERA II open label extension study. Multiple Sclerosis Journal2018;24(2):NP8-9. PapeixC , CreeB , TurnerB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):332-3. ParrattJ , HauserSL , KapposL , MontalbanX , Bar-OrA , GiovannoniG , et al.Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP66-7. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. SelmajK , ArnoldD , Bar-OrA , ComiG , Hartung H-P, HauserS , et al.Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a controlled OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):202. SongZ , KrishnanA , GaetanoL , ClaytonD , De CrespignyA , BengtssonT , et al.Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry. Multiple Sclerosis Journal2020;26(3 Suppl):411. TraboulseeA , ArnoldD , Bar-OrA , ComiG , Hartung H-P, KapposL , et al.Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies. European Journal of Neurology2016;23(Suppl 2):58. TraboulseeA , GiovannoniG , Bar-OrA , ComiG , Hartung H-P, HavrdováE , et al.NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies. Multiple Sclerosis2017;23(Suppl 1):18-9. TraboulseeA , HauserS , HavrdovaE , KapposL , RackeM , SelmajK , et al.Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies. Neurology2017;88(16 Suppl 1):Meeting abstract. TurnerB , CreeBA , KapposL , MontalbanX , PapeixC , WolinskyJS , et al.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology2019;266(5):1182-93. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II. European Journal of Neurology2018;25(Suppl 2):534. TurnerB , PapeixC , CreeB , KapposL , MontalbanX , WolinskyJS , et al.Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):333-4. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ">OPERA II 2017</a>). The mean percentage change was less with ocrelizumab than with interferon beta‐1a (MD 0.14, 95% CI 0.05 to 0.23; P = 0.003; I² = 0%; 1656 participants; fixed‐effect model; <a href="./references#CD013247-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> </section> <section id="CD013247-sec-0068"> <h4 class="title">Comparison 2: ocrelizumab 600 mg versus placebo for relapsing‐remitting multiple sclerosis </h4> <p>We were unable to conduct meta‐analysis because only one study was included. Thus, we have provided a descriptive summary of the results. <a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> compared ocrelizumab versus placebo for treating RRMS at 24 weeks. </p> <section id="CD013247-sec-0069"> <h5 class="title">Primary outcomes: benefits</h5> <section id="CD013247-sec-0070"> <h6 class="title">Number of participants experiencing at least one relapse</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> reported the number of participants experiencing at least one relapse at 24 weeks. The rate was lower with ocrelizumab than with placebo (RR 0.18, 95% CI 0.06 to 0.60; P = 0.005; 109 participants; <a href="./references#CD013247-fig-0013" title="">Analysis 2.1</a>). </p> </section> <section id="CD013247-sec-0071"> <h6 class="title">Number of participants experiencing disability progression</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> did not assess the number of participants experiencing disability progression. </p> </section> </section> <section id="CD013247-sec-0072"> <h5 class="title">Primary outcomes: harms</h5> <section id="CD013247-sec-0073"> <h6 class="title">Number of participants experiencing any adverse event</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> reported the number of participants experiencing any adverse events at 24 weeks. There was little to no difference between groups (RR 0.88, 95% CI 0.67 to 1.15; P = 0.35; 109 participants; <a href="./references#CD013247-fig-0014" title="">Analysis 2.2</a>). </p> </section> <section id="CD013247-sec-0074"> <h6 class="title">Number of participants experiencing any serious adverse events</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> reported the number of participants experiencing any serious adverse events at 24 weeks. There was little to no difference between groups (RR 0.49, 95% CI 0.05 to 5.26; P = 0.56; 109 participants; <a href="./references#CD013247-fig-0015" title="">Analysis 2.3</a>). </p> </section> <section id="CD013247-sec-0075"> <h6 class="title">Number of participants experiencing treatment discontinuation caused by adverse events</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> reported the number of participants experiencing treatment discontinuation caused by adverse events at 24 weeks. There was little to no difference between groups (RR 4.91, 95% CI 0.24 to 99.97; P = 0.30; 109 participants; <a href="./references#CD013247-fig-0016" title="">Analysis 2.4</a>). </p> </section> </section> <section id="CD013247-sec-0076"> <h5 class="title">Secondary outcomes</h5> <section id="CD013247-sec-0077"> <h6 class="title">Change in quality of life</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> did not assess quality of life. </p> </section> <section id="CD013247-sec-0078"> <h6 class="title">Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging </h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> reported the number of participants with gadolinium‐enhancing T1 lesions on MRI at 24 weeks. The rate was lower with ocrelizumab than with placebo (RR 0.34, 95% CI 0.20 to 0.58; P &lt; 0.0001; 109 participants; <a href="./references#CD013247-fig-0017" title="">Analysis 2.5</a>). </p> </section> <section id="CD013247-sec-0079"> <h6 class="title">Number of participants with new or enlarging T2‐hyperintense lesions on magnetic resonance imaging </h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> did not assess number of participants with new or enlarging T2‐hyperintense lesions on MRI. </p> </section> <section id="CD013247-sec-0080"> <h6 class="title">Mean percentage change in brain‐volume from week 24 to the end of the study</h6> <p><a href="./references#CD013247-bbs2-0001" title="BakerD , PryceG , JamesLK , MartaM , SchmiererK .The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders2020;44:102279. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP14-15. BarkhofF , KapposL , Bar-OrA , LiD , BelachewS , JulianL , et al.Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. HauserS , KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , et al.Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial. Neurology2012;78(1):Meeting abstract. HauserS , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis. Neurology2013;80(1):Meeting abstract. KapposL , Bar-OrA , SauterA , LeppertD , LiD , MastermanD , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(12):1875. KapposL , CalabresiP , O'ConnorP , Bar-OrA , LiD , BarkhofF , et al.Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2010;16(10 Suppl 1):S33-S34. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):140-1. KapposL , LiD , CalabresiP , O'ConnorP , Bar-OrA , BarkhofF , et al.Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis. Journal of Neurology2012;259(Suppl 1):S65. KapposL , LiD , CalabresiPA , O'ConnorP , Bar-OrA , BarkhofF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011;378(9805):1779-87. ZhaoY , LiDK , RiddehoughA , TraboulseeA , MastermanD , GilbergF , et al.Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis2012;18(4 Suppl 1):446-7. ">Kappos 2011</a> did not assess mean percentage change in brain‐volume from week 24 to the end of the study. </p> </section> </section> </section> <section id="CD013247-sec-0081"> <h4 class="title">Comparison 3: ocrelizumab 600 mg versus placebo for primary progressive multiple sclerosis</h4> <p>We were unable to conduct meta‐analysis because only one study was included. Thus, we have provided a descriptive summary of the results. <a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> compared ocrelizumab versus placebo for treating PPMS for at least 120 weeks (see <a href="./full#CD013247-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD013247-sec-0082"> <h5 class="title">Primary outcomes: benefits</h5> <section id="CD013247-sec-0083"> <h6 class="title">Number of participants experiencing at least one relapse</h6> <p>This outcome is not applicable to PPMS.</p> </section> <section id="CD013247-sec-0084"> <h6 class="title">Number of participants experiencing disability progression</h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> reported that the number of participants with 24‐week confirmed disability progression was 29.6% with ocrelizumab and 35.7% with placebo. The rate of participants experiencing 24‐week confirmed disability progression was lower with ocrelizumab than with placebo (HR 0.75, 95% CI 0.58 to 0.98; P = 0.03; 731 participants; <a href="./references#CD013247-fig-0018" title="">Analysis 3.1</a>). (We used HR to calculate this outcome due to time‐to‐event data.) </p> </section> </section> <section id="CD013247-sec-0085"> <h5 class="title">Primary outcomes: harms</h5> <section id="CD013247-sec-0086"> <h6 class="title">Number of participants experiencing any adverse event</h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> reported that in the ocrelizumab group, 462/486 (95.1%) participants experienced any adverse events and in the placebo group, 215/239 (90.0%) participants experienced any adverse events. The rate was higher with ocrelizumab than with placebo (RR 1.06, 95% CI 1.01 to 1.11; P = 0.02; 725 participants; <a href="./references#CD013247-fig-0019" title="">Analysis 3.2</a>). </p> </section> <section id="CD013247-sec-0087"> <h6 class="title">Number of participants experiencing any serious adverse events</h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> reported that in the ocrelizumab group, 99/486 (20.4%) participants experienced any serious adverse events and in the placebo group, 53/239 (22.2%) participants experienced any serious adverse events. There was little to no difference between groups (RR 0.92, 95% CI 0.68 to 1.23; P = 0.57; 725 participants; <a href="./references#CD013247-fig-0020" title="">Analysis 3.3</a>). </p> </section> <section id="CD013247-sec-0088"> <h6 class="title">Number of participants experiencing treatment discontinuation caused by adverse events</h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> reported that 20/486 (4.1%) participants in the ocrelizumab group experienced treatment discontinuation caused by adverse events and 8/239 (3.3%) participants in the placebo group experienced treatment discontinuation caused by adverse events. There was little to no difference between groups (RR 1.23, 95% CI 0.55 to 2.75; P = 0.62; 725 participants; <a href="./references#CD013247-fig-0021" title="">Analysis 3.4</a>). </p> </section> </section> <section id="CD013247-sec-0089"> <h5 class="title">Secondary outcomes</h5> <section id="CD013247-sec-0090"> <h6 class="title">Change in quality of life</h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> reported the change in SF‐36 Physical Component Summary score from baseline to week 120. There was little to no difference between groups (adjusted MD 0.38, 95% CI −1.04 to 1.80; P = 0.60; 732 participants; <a href="./references#CD013247-fig-0022" title="">Analysis 3.5</a>). </p> </section> <section id="CD013247-sec-0091"> <h6 class="title">Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging </h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> did not assess number of participants with gadolinium‐enhancing T1 lesions on MRI. </p> </section> <section id="CD013247-sec-0092"> <h6 class="title">Number of participants with new or enlarging T2‐hyperintense lesions on magnetic resonance imaging </h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> did not assess number of participants with new or enlarging T2‐hyperintense lesions on MRI. </p> </section> <section id="CD013247-sec-0093"> <h6 class="title">Mean percentage change in brain‐volume from week 24 to the end of the study</h6> <p><a href="./references#CD013247-bbs2-0004" title="ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I/OPERA II and ORATORIO. European Journal of Neurology2021;28(Suppl 1):120. ArnoldD , AssemlalH , TraboulseeA , KolindS , SprengerT , Bar-OrA , et al.Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I/II and ORATORIO. Multiple Sclerosis Journal2020;26(3 Suppl):8. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial. European Journal of Neurology2019;26(Suppl 1):157. ArnoldDL , GiovannoniG , Hartung H-P, HauserSL , KapposL , MontalbanX , et al.Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up. Neurology2019;92(15 Suppl 1):Meeting abstract. Bar-OrA , BermelR , WeberMS , HughesR , Lin C-J, WangJ , et al.Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis. Neurology2020;94(15 Suppl):Meeting abstract. Bar-OrA , HermanA , HarpC , CrossA , FioreD , HauserSL , et al.Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab. Multiple Sclerosis Journal2020;26(1 Suppl):17. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossA , et al.Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS. Multiple Sclerosis Journal2020;26(3 Suppl):178-9. Bar-OrA , ThaneiG , HarpC , BernasconiC , BonatiU , CrossAH , et al.Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity. Multiple Sclerosis Journal2020;26(3 Suppl):177. Bar-OrA , Thanei G-A, HarpC , CrossA , FioreD , HauserS , et al.Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials. Neurology2020;94(15):Meeting abstract. Bar-OrA , Thanei G-A, HarpC , CrossA , HauserS , JiaX , et al.Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2020;27(Suppl 1):197. ButzkuevenH , SpelmanT , HorakovaD , HughesS , SolaroC , IzquierdoG , et al.Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. European Journal of Neurology2022;29(4):1082-90. ButzkuevenH , SpelmanT , HorakovaD , SleeM , HughesS , SolaroC , et al.Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry. European Journal of Neurology2018;26(Suppl 2):320-1. DerfussT , WeberM , HughesR , EggebrechtJ , WangQ , SauterA , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical Neurophysiology2020;131(4):e196. DerfussT , WeberMS , HughesR , WangQ , SauterA , KoendgenH , et al.Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Multiple Sclerosis Journal2019;25(Suppl 2):20-1. De SèzeJ , ArnoldDL , Bar-OrA , GiovannoniG , Hartung H-P, HauserSL , et al.Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):351-2. De SèzeJ , HauserSL , KapposL , MontalbanX , PozzilliC , ChognotC , et al.Infusion-related reactions with ocrelizumab in phase III studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):878-9. De SèzeJ , MontalbanX , McDougallF , JulianL , SauterA , Deol-BhullarG , et al.Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2017;23(Suppl 1):84. De SèzeJ , MontalbanX , McDougallF , SauterA , Deol-BhullarG , WolinskyJ .Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):677-8. ElliottC , BelachewS , WolinskyJS , HauserSL , KapposL , BarkhofF , et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain2019;142(9):2787-99. ElliottC , WolinskyJ , HauserS , KapposL , BarkhofF , ModelF , et al.Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. FoxE , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore). Journal of Neurology, Neurosurgery and Psychiatry2018;89(6):e14. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO. Multiple Sclerosis Journal2018;24(1 Suppl 1):33-4. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis Journal2017;23(3 Suppl 1):658-9. FoxEJ , MarkowitzC , ApplebeeA , MontalbanX , WolinskyJS , BelachewS , et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal2018;24(14):1862-70. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Multiple Sclerosis Journal2018;24(2 Suppl):306-7. GiovannoniG , AirasL , BoveR , BoykoA , CutterG , HobartJ , et al.Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design. Neurology2019;92(15 Suppl 1):Meeting abstract. GiovannoniG , ArnoldDL , Bar-OrA , De SèzeJ , HemmerB , MontalbanX , et al.An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):371-2. GiovannoniG , De SèzeJ , KapposL , MontalbanX , HauserSL , BelachewS , et al.An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):494. Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SèzeJ , GiovannoniG , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis2016;22(Suppl 3):658-9. HauserSL , De SèzeJ , KapposL , MontalbanX , PozzilliC , GuittariCJ , et al.Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions. Multiple Sclerosis Journal2018;24(1 Suppl 1):46. HauserSL , KapposL , MontalbanX , ChinP , GreenMC , KoendgenH , et al.Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. Multiple Sclerosis Journal2017;23(3 Suppl 1):331-2. HauserSL , KapposL , MontalbanX , GuittariCJ , KoendgenH , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(3 Suppl 1):324-5. HauserSL , KapposL , MontalbanX , HughesR , KoendgenH , McNamaraJ , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Multiple Sclerosis Journal2018;24(2):NP13. HauserSL , KapposL , MontalbanX , KoendgenH , LiC , MarcillatC , et al.Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. European Journal of Neurology2018;25(Suppl 2):334. HauserSL , WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis and Related Disorders2018;26:264-5. JiaX , HermanA , HarpC , CrossA , FioreD , HauserS , et al.Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment. Neurology2020;94(15 Suppl):Meeting abstract. KapposL , GiovannoniG , De SèzeJ , MontalbanX , WolinskyJ , BelachewS , et al.Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis. European Journal of Neurology2017;24(Suppl 1):44. KapposL , HauserS , MontalbanX , BuffelsR , ChinP , LiC , et al.Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis. Neurology2017;88(16 Suppl 1):Meeting abstract. KapposL , MontalbanX , HauserSL , JulianL , ManfriniM , BelachewS , et al.Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study. European Journal of Neurology2018;25(Suppl 2):431. KuheljR , Deol-BhullarG , GarasM , ChinP , HauserS , MontalbanX .Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS. European Journal of Neurology2016;23(Suppl 2):200. MayerL , KapposL , RackeMK , RammohanK , TraboulseeA , HauserSL , et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders2019;30:236-43. MillerD , HauserS , KapposL , LublinF , MontalbanX , McDougallF , et al.The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study. Neurology2017;88(16 Suppl 1):Meeting abstract. MontalbanX , ArnoldD , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS). European Journal of Neurology2016;23(Suppl 2):410. MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , HemmerB , et al.Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2016;22(Suppl 3):50-1. MontalbanX , HauserSL , KapposL , ArnoldDL , Bar-OrA , ComiG , et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine2017;376(3):209-20. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. European Journal of Neurology2015;22(Suppl 1):705. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis. Neurology2015;84(Suppl 14):Meeting abstract. MontalbanX , HemmerB , RammohanK , GiovannoniG , De SèzeJ , Bar-OrA , et al.Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study. Multiple Sclerosis2015;23(11 Suppl 1):781-2. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. European Journal of Neurology2017;24(Suppl 1):576. MontalbanX , WolinskyJ , KapposL , HauserSL , GiovannoniG , De SèzeJ , et al.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis Journal2018;24(2):NP10. RammohanKW , Hartung H-P, ArnoldDL , Bar-OrA , ComiG , De SezeJ , et al.Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis. Multiple Sclerosis Journal2017;23(Suppl 1):31-2. TaylorB , WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]. Multiple Sclerosis Journal2020;26(9):NP37. WolinskyJ , KapposL , MontalbanX , ChognotC , KoendgenH , LiC , et al.Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis. Neurology2018;90(15 Suppl 1):Meeting abstract. WolinskyJ , McDougallF , LentzE , Deol-BhullarG , MontalbanX .Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study. Multiple Sclerosis2016;22(Suppl 3):676-7. WolinskyJ , MontalbanX , ArnoldDL , Bar-OrA , De SèzeJ , GiovannoniG , et al.Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Multiple Sclerosis2017;23(Suppl 1):17. WolinskyJ , MontalbanX , KapposL , HauserS , GiovannoniG , De SèzeJ , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Neurology2017;88(16 Suppl 1):Meeting abstract. WolinskyJ , VermerschP , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up. Multiple Sclerosis Journal2020;26(3 Suppl):234-5. WolinskyJS , ArnoldDL , BrochetB , HartungHP , MontalbanX , NaismithRT , et al.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurology2020;19(12):998-1009. WolinskyJS , BrochetB , HartungH , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data. Multiple Sclerosis Journal2020;26(1 Suppl):49-50. WolinskyJS , BrochetB , HartungHP , NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Journal of the Neurological Sciences2019;405(Suppl):31. WolinskyJS , BrochetB , Hartung H-P, NaismithRT , AirasL , CoutantK , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data. Multiple Sclerosis Journal2019;25(Suppl 2):56-7. WolinskyJS , BrochetB , MontalbanX , NaismithRT , ManfriniM , GarasM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Multiple Sclerosis Journal2018;24(2 Suppl):490-1. WolinskyJS , HartungHP , BrochetB , MontalbanX , NaismithRT , ManfriniM , et al.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Clinical Neurophysiology2019;130(8):e170-1. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. European Journal of Neurology2019;26(Suppl 1):322. WolinskyJS , KapposL , MontalbanX , ModelF , MehtaL , HubeauxS , et al.Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis. Neurology2019;92(15 Suppl 1):Meeting abstract. WolinskyJS , MontalbanX , HauserSL , GiovannoniG , VermerschP , BernasconiC , et al.Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology2018;84(4):527-36. WolinskyJS , MontalbanX , HauserSL , ModelF , Deol-BhullarG , GarrenH , et al.Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period. Multiple Sclerosis Journal2017;23(3 Suppl 1):656-7. XuY , HanJ , MaX , PeiJ , EngmannNJ , PradhanA , et al.An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability. Value in Health2018;21(Suppl 3):S330. ZivadinovR , PeiJ , ClaytonD , GoldmanD , WingerR , RamasamyD , et al.Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study. Neurology2021;96(15 Suppl 1):Meeting abstract. ">ORATORIO 2017</a> reported that the adjusted mean percentage change in brain volume from week 24 to week 120 was lower with ocrelizumab than with placebo (MD 0.19, 95% CI 0.01 to 0.37; P = 0.03; 732 participants; <a href="./references#CD013247-fig-0023" title="">Analysis 3.6</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013247-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013247-sec-0094"></div> <section id="CD013247-sec-0095"> <h3 class="title" id="CD013247-sec-0095">Summary of main results</h3> <p>This systematic review aimed to evaluate the benefits, harms, and tolerability of ocrelizumab compared with placebo or any other drug treatments for RRMS or PPMS. </p> <p>For RRMS, based on the results of two RCTs, compared to interferon beta‐1a, ocrelizumab 600 mg: </p> <p> <ol id="CD013247-list-0015"> <li> <p>probably reduces the relapse rate at 96 weeks;</p> </li> <li> <p>may reduce the number of participants with disability progression at 96 weeks;</p> </li> <li> <p>probably results in little to no difference in the number of participants with any adverse events at 96 weeks; </p> </li> <li> <p>may result in little to no difference in the number of participants with any serious adverse events at 96 weeks; </p> </li> <li> <p>may reduce the number of participants experiencing treatment discontinuation caused by adverse events at 96 weeks; </p> </li> <li> <p>may reduce the number of participants with gadolinium‐enhancing T1 lesions on MRI at 96 weeks; </p> </li> <li> <p>may reduce the number of participants with new or enlarging T2‐hyperintense lesions on MRI at 96 weeks. </p> </li> </ol> </p> <p>For PPMS, based on the results of one RCT, compared to placebo, ocrelizumab 600 mg:</p> <p> <ol id="CD013247-list-0016"> <li> <p>may reduce the number of participants with disability progression at 120 weeks;</p> </li> <li> <p>probably increases the number of adverse events at 120 weeks;</p> </li> <li> <p>may result in little to no difference in the number of participants with any serious adverse event at 120 weeks; </p> </li> <li> <p>may result in little to no difference in the number of participants experiencing treatment discontinuation caused by adverse events at 120 weeks. </p> </li> </ol> </p> </section> <section id="CD013247-sec-0096"> <h3 class="title" id="CD013247-sec-0096">Overall completeness and applicability of evidence</h3> <p>In this review, we included three RCTs that evaluated the benefit of ocrelizumab as monotherapy versus interferon beta‐1a or placebo for RRMS and one RCT that compared ocrelizumab versus placebo for PPMS. For RRMS, two identical RCTs contributed to the main evidence. Participants randomly received intravenous ocrelizumab 600 mg every 24 weeks or subcutaneous interferon beta‐1a 44 μg three times weekly for 96 weeks. For PPMS, participants randomly received intravenous ocrelizumab 600 mg or placebo every 24 weeks for at least 120 weeks. It is important to note that MS is a chronic disease, and treatment of MS requires adequate duration of medication and follow‐up to determine benefits, harms, and tolerability outcomes, adding to the uncertainty of these findings. </p> <p>We selected outcome measures that evaluated benefits (relapse rate, disability progression), harms (adverse events and serious adverse events), tolerability (treatment discontinuation caused by adverse events), and MRI appearance (gadolinium‐enhancing T1 lesions and new or newly enlarging T2‐hyperintense lesions). We performed meta‐analyses using the available data from the studies. The small number of included studies and the absence of data on people receiving treatment over a longer time (e.g. 144 weeks or longer) might increase the uncertainty of these findings. Besides, changes in MRI were not consistently proved closely related to changes in disability progression. Further, the studies only included people with RRMS and PPMS, and we found no evidence for other forms of MS. </p> <p>In summary, the above limitations may affect the applicability of the evidence. The available evidence is limited to these specific interventions and patients, and requires us to be cautious in interpreting the results. </p> </section> <section id="CD013247-sec-0097"> <h3 class="title" id="CD013247-sec-0097">Quality of the evidence</h3> <p>As shown in <a href="./full#CD013247-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013247-tbl-0002">summary of findings Table 2</a>, the certainty of evidence for each outcome ranged from low to moderate. </p> <p>The certainty of evidence for all included outcomes for RRMS at 96 weeks were downgraded due to a high rate of dropouts and unbalanced dropouts between ocrelizumab and interferon beta‐1a groups. The certainty of evidence for disability progression, any serious adverse events, and discontinuation caused by adverse events were downgraded due to insufficient information size and wide 95% CIs. The quality of evidence for two MRI outcomes were downgraded due to indirectness. Overall, we gave a GRADE rating of moderate for relapses and any adverse events, and low for disability progression, any serious adverse events, discontinuation caused by adverse events, MRI gadolinium‐enhancing T1 lesions and MRI new or newly enlarging T2‐hyperintense lesions. </p> <p>The certainty of evidence for all included outcomes for PPMS for at least 120 weeks were downgraded due to a high rate of dropouts and unbalanced dropouts between ocrelizumab and placebo groups. The certainty of evidence for disability progression, any serious adverse events, and discontinuation caused by adverse events were downgraded due to insufficient information size and wide 95% CIs. Overall, we gave a GRADE rating of moderate for any adverse events, and low for disability progression, any serious adverse events, and discontinuation caused by adverse events. </p> </section> <section id="CD013247-sec-0098"> <h3 class="title" id="CD013247-sec-0098">Potential biases in the review process</h3> <p>To avoid the introduction of bias, we strictly followed the recommendations on searching, study selection, quality assessment, data collection, and data analysis from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013247-bbs2-0015" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). The search strategy for the studies was broad and sensitive, which suggests the likelihood that all RCTs were identified. The authors of this review had no conflicts of interest. </p> <p>The limitation of this review include:</p> <p> <ol id="CD013247-list-0017"> <li> <p>lack of outcome data in the included studies;</p> </li> <li> <p>publication bias was not assessed by funnel plot analysis because fewer than 10 studies were included in the meta‐analysis. </p> </li> </ol> </p> </section> <section id="CD013247-sec-0099"> <h3 class="title" id="CD013247-sec-0099">Agreements and disagreements with other studies or reviews</h3> <p>This review included four RCTs and evaluated the benefits, harms, and tolerability of ocrelizumab in RRMS and PPMS. We found similar reviews that included and evaluated the use of ocrelizumab in MS, and these reviews differed slightly in their analytical approach, but overall, they reached similar conclusions (<a href="./references#CD013247-bbs2-0021" title="McCoolR , WilsonK , ArberM , FleetwoodK , ToupinS , ThomH , et al.Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders2019;29:55-61.">McCool 2019</a>; <a href="./references#CD013247-bbs2-0023" title="NgHS , RosenbultCL , TremlettH .Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opinion On Drug Safety2020;19(9):1069-94.">Ng 2020</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013247-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013247-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013247-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013247-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 1: Number of participants experiencing at least one relapse by the end of the study" data-id="CD013247-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 1: Number of participants experiencing at least one relapse by the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 2: Number of participants experiencing disability progression by the end of the study" data-id="CD013247-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 2: Number of participants experiencing disability progression by the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 3: Number of participants with any adverse events" data-id="CD013247-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 3: Number of participants with any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 4: Number of participants with any serious adverse events" data-id="CD013247-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 4: Number of participants with any serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 5: Number of participants experiencing treatment discontinuation caused by adverse events" data-id="CD013247-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 5: Number of participants experiencing treatment discontinuation caused by adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 6: Change in SF‐36 physical‐component summary score from baseline to the end of the study" data-id="CD013247-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 6: Change in SF‐36 physical‐component summary score from baseline to the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 7: Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging (MRI) by the end of the study" data-id="CD013247-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 7: Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging (MRI) by the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 8: Number of participants with new or newly enlarged T2‐hyperintense lesions on MRI by the end of the study" data-id="CD013247-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 8: Number of participants with new or newly enlarged T2‐hyperintense lesions on MRI by the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 9: Mean percentage change in brain volume from week 24 to the end of the study" data-id="CD013247-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis, Outcome 9: Mean percentage change in brain volume from week 24 to the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 1: Number of participants experiencing at least one relapse by the end of the study" data-id="CD013247-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 1: Number of participants experiencing at least one relapse by the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 2: Number of participants with any adverse events" data-id="CD013247-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 2: Number of participants with any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 3: Number of participants with any serious adverse events" data-id="CD013247-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 3: Number of participants with any serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 4: Number of participants experiencing treatment discontinuation caused by adverse events" data-id="CD013247-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 4: Number of participants experiencing treatment discontinuation caused by adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 5: Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging by the end of the study" data-id="CD013247-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis, Outcome 5: Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging by the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 1: Number of participants experiencing disability progression by the end of the study" data-id="CD013247-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 1: Number of participants experiencing disability progression by the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 2: Number of participants with any adverse events" data-id="CD013247-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 2: Number of participants with any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 3: Number of participants with any serious adverse events" data-id="CD013247-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 3: Number of participants with any serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 4: Number of participants experiencing treatment discontinuation caused by adverse events" data-id="CD013247-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 4: Number of participants experiencing treatment discontinuation caused by adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 5: Change in SF‐36 Physical Component Summary score from baseline to the end of the study" data-id="CD013247-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 5: Change in SF‐36 Physical Component Summary score from baseline to the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013247-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/urn:x-wiley:14651858:media:CD013247:CD013247-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 6: Mean percentage change in brain volume from week 24 to the end of the study" data-id="CD013247-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_t/tCD013247-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Ocrelizumab versus placebo for primary progressive multiple sclerosis, Outcome 6: Mean percentage change in brain volume from week 24 to the end of the study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/media/CDSR/CD013247/image_n/nCD013247-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013247-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ocrelizumab compared to interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ocrelizumab compared to interferon beta‐1a for relapsing‐remitting multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with relapsing‐remitting multiple sclerosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ocrelizumab<br/><b>Comparison:</b> interferon beta‐1a </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with interferon beta‐1a</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with ocrelizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing ≥ 1 relapse</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.61</b><br/>(0.52 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1000<br/>(201 to 274) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing disability progression</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.60</b><br/>(0.43 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000<br/>(50 to 94) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any adverse events</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b><br/>(0.96 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1000<br/>(800 to 866) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any serious adverse events</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.79</b><br/>(0.57 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000<br/>(50 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse events</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.58</b><br/>(0.37 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/>(22 to 55) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with gadolinium‐enhancing T1 lesions on MRI</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.27</b><br/>(0.22 to 0.35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>331 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/>(73 to 116) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with new or enlarging T2‐hyperintense lesions on MRI</b> </p> <p>Follow‐up: 96 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.63</b><br/>(0.57 to 0.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>616 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>388 per 1000<br/>(351 to 425) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MRI:</b> magnetic resonance imaging; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to study limitation (a high rate of dropouts existed and reasons of dropouts were unbalanced between arms).<br/><sup>b</sup>Downgraded one level due to imprecision (total number of events (i.e. the number of participants experiencing disability progression, the number of participants with any serious adverse events and the number of participants experiencing treatment discontinuation caused by adverse events) was fewer than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size (OIS) criteria. Wide 95% confidence intervals).<br/><sup>c</sup>Downgraded one level due to indirectness (changes in MRI (gadolinium‐enhancing T1 lesions or new or newly enlarging T2‐hyperintense lesions) were not consistently proved closely related to changes in disability progression). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ocrelizumab compared to interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013247-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ocrelizumab compared to placebo for primary progressive multiple sclerosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ocrelizumab compared to placebo for primary progressive multiple sclerosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with primary progressive multiple sclerosis<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ocrelizumab<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with ocrelizumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing disability progression</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.75</b><br/>(0.58 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>731<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>357 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(239 to 367) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any adverse events</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.06</b><br/>(1.01 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>725<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>954 per 1000<br/>(909 to 999) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with any serious adverse events</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.92</b><br/>(0.68 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>725<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000<br/>(151 to 273) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants experiencing treatment discontinuation caused by adverse event</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.23</b><br/>(0.55 to 2.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>725<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/>(18 to 92) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with gadolinium‐enhancing T1 lesions on MRI</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with new or enlarging T2‐hyperintense lesions on MRI</b> </p> <p>Follow‐up: ≥ 120 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to study limitation (a high rate of dropouts existed and reasons of dropouts were unbalanced between arms).<br/><sup>b</sup>Downgraded one level due to imprecision (total number of events (i.e. the number of participants experiencing disability progression, the number of participants with any serious adverse events, and the number of participants experiencing treatment discontinuation caused by adverse events) was fewer than 300 (the threshold rule‐of‐thumb value), and thus the available evidence did not meet the optimal information size (OIS) criteria. Wide 95% confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ocrelizumab compared to placebo for primary progressive multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/full#CD013247-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013247-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of participants experiencing at least one relapse by the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 at 96 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.52, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Number of participants experiencing disability progression by the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.43, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of participants with any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.81, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 at 96 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Number of participants with any serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 at 96 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Number of participants experiencing treatment discontinuation caused by adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.18, 21.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 at 96 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.37, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Change in SF‐36 physical‐component summary score from baseline to the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.02, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging (MRI) by the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.25, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 at 96 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.22, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Number of participants with new or newly enlarged T2‐hyperintense lesions on MRI by the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.57, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Mean percentage change in brain volume from week 24 to the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.05, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ocrelizumab versus interferon beta‐1a for relapsing‐remitting multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013247-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Number of participants experiencing at least one relapse by the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.06, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Number of participants with any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Number of participants with any serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.05, 5.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Number of participants experiencing treatment discontinuation caused by adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [0.24, 99.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Number of participants with gadolinium‐enhancing T1 lesions on magnetic resonance imaging by the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.20, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ocrelizumab versus placebo for relapsing‐remitting multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013247-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ocrelizumab versus placebo for primary progressive multiple sclerosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Number of participants experiencing disability progression by the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.58, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Number of participants with any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.01, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Number of participants with any serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.68, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Number of participants experiencing treatment discontinuation caused by adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.55, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Change in SF‐36 Physical Component Summary score from baseline to the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐1.04, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Mean percentage change in brain volume from week 24 to the end of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ocrelizumab versus placebo for primary progressive multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013247.pub2/references#CD013247-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013247.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013247-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013247-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013247-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD013247-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013247-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD013247-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD013247-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013247-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013247-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013247\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013247\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013247\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013247\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013247\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013247.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013247.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013247.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013247.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013247.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727931497"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013247.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727931501"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013247.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb814984e937f',t:'MTc0MDcyNzkzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 